Glaukos (NYSE: GKOS) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it compare to its rivals? We will compare Glaukos to similar companies based on the strength of its valuation, profitability, risk, earnings, dividends, institutional ownership and analyst recommendations.
This table compares Glaukos and its rivals’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Earnings and Valuation
This table compares Glaukos and its rivals gross revenue, earnings per share and valuation.
Glaukos’ rivals have higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Glaukos has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Comparatively, Glaukos’ rivals have a beta of 0.95, meaning that their average share price is 6% less volatile than the S&P 500.
This is a breakdown of recent ratings and target prices for Glaukos and its rivals, as reported by MarketBeat.
||Strong Buy Ratings
Glaukos presently has a consensus target price of $47.50, indicating a potential upside of 84.32%. As a group, “Medical Devices & Implants” companies have a potential upside of 37.35%. Given Glaukos’ stronger consensus rating and higher probable upside, equities analysts plainly believe Glaukos is more favorable than its rivals.
Institutional & Insider Ownership
99.2% of Glaukos shares are held by institutional investors. Comparatively, 54.8% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 16.4% of Glaukos shares are held by company insiders. Comparatively, 11.9% of shares of all “Medical Devices & Implants” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Glaukos beats its rivals on 10 of the 13 factors compared.
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.